Clinical Trials
1,248 trialsTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
eVOLVECervical
AstraZeneca
NAPISTAR1-01
Tubulis GmbH
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
FRAmework-01
Eli Lilly and Company
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Boehringer Ingelheim
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
RAINFOL-01
Genmab
PAROLA
Institut Claudius Regaud
EVEREST-2
A2 Biotherapeutics Inc.
eVOLVE-02
AstraZeneca
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
RSPH5973-23
Emory University
DO-01
Daiichi Sankyo
MK-5909-003
Merck Sharp & Dohme LLC
MAESTRA 1
Incyte Corporation
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
National Cancer Institute (NCI)
MAESTRA 2
Incyte Corporation
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Stemline Therapeutics, Inc.
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
PIPACOVA
Hospices Civils de Lyon
SCOUT-1
AstraZeneca
VERDI
Dana-Farber Cancer Institute
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
PIKALO-1
Eli Lilly and Company
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co., Ltd.
NEXUS-01
Eli Lilly and Company
BIOC
KU Leuven
TroFuse-033
Merck Sharp & Dohme LLC
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
OMNIRAY
Eli Lilly and Company
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
FiREBOLT
Eli Lilly and Company
TroFuse-036
Merck Sharp & Dohme LLC
TroFuse-021
Merck Sharp & Dohme LLC
PRSTEC_multipr
University Hospital Hradec Kralove
CASCADE3001A
UNC Lineberger Comprehensive Cancer Center
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Quality of Life and Function of Patients With Pelvic Tumors After Undergoing Hemipelvectomy
M.D. Anderson Cancer Center
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fern-EC-01
BioNTech SE
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Oncoinvent Solutions AS